MX2017009960A - Union de rutenio e indio unidos a las gastrinas. - Google Patents

Union de rutenio e indio unidos a las gastrinas.

Info

Publication number
MX2017009960A
MX2017009960A MX2017009960A MX2017009960A MX2017009960A MX 2017009960 A MX2017009960 A MX 2017009960A MX 2017009960 A MX2017009960 A MX 2017009960A MX 2017009960 A MX2017009960 A MX 2017009960A MX 2017009960 A MX2017009960 A MX 2017009960A
Authority
MX
Mexico
Prior art keywords
gastrins
ruthenium
indium
conditions
binding
Prior art date
Application number
MX2017009960A
Other languages
English (en)
Inventor
Eutick Malvin
Original Assignee
Eupharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900343A external-priority patent/AU2015900343A0/en
Application filed by Eupharma Pty Ltd filed Critical Eupharma Pty Ltd
Publication of MX2017009960A publication Critical patent/MX2017009960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se apoya en la unión de alta afinidad del rutenio e indio con gastrinas, no lograda hasta ahora. En particular, estos metales se pueden unir directamente con las gastrinas en condiciones moderadas y pueden usarse en el tratamiento de padecimientos asociados con elevados niveles de gastrina y en la detección de tumores y otros padecimientos en los que el receptor CCKs sobreexpresado.
MX2017009960A 2015-02-04 2016-02-04 Union de rutenio e indio unidos a las gastrinas. MX2017009960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015900343A AU2015900343A0 (en) 2015-02-04 Ruthenium and indium binding to gastrins
PCT/AU2016/050063 WO2016123670A1 (en) 2015-02-04 2016-02-04 Ruthenium and indium binding to gastrins

Publications (1)

Publication Number Publication Date
MX2017009960A true MX2017009960A (es) 2017-11-15

Family

ID=56563239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009960A MX2017009960A (es) 2015-02-04 2016-02-04 Union de rutenio e indio unidos a las gastrinas.

Country Status (11)

Country Link
US (1) US20180021373A1 (es)
EP (1) EP3253421A4 (es)
JP (1) JP2018504428A (es)
KR (1) KR20170113609A (es)
CN (1) CN107427593A (es)
AU (1) AU2016214973A1 (es)
CA (1) CA2975625A1 (es)
IL (1) IL253785A0 (es)
MX (1) MX2017009960A (es)
SG (1) SG11201706285VA (es)
WO (1) WO2016123670A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201927343A (zh) * 2017-12-08 2019-07-16 瑞士商Ｅｃｓ生物識別系統有限公司 癌症診斷中之經放射標記的前胃泌激素
WO2024083224A1 (en) * 2022-10-20 2024-04-25 Full-Life Technologies Hk Limited Dual receptor targeting radioligands and uses thereof related applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180082B1 (en) * 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
CN1750838A (zh) * 2003-02-20 2006-03-22 席堤克株式会社 含有贵金属微粒的药品
WO2004073723A1 (ja) * 2003-02-20 2004-09-02 She Tec Co., Ltd. 貴金属微粒子を含む医薬
WO2004089976A1 (en) * 2003-04-08 2004-10-21 The University Of Melbourne Method of treatment
CN101203249A (zh) * 2005-04-01 2008-06-18 德克萨斯大学体系董事会 多（肽）作为螯合剂：制造方法和用途
GB0604602D0 (en) * 2006-03-07 2006-04-19 Univ Edinburgh Ruthenium (II) compounds

Also Published As

Publication number Publication date
EP3253421A4 (en) 2018-10-17
EP3253421A1 (en) 2017-12-13
CN107427593A (zh) 2017-12-01
US20180021373A1 (en) 2018-01-25
IL253785A0 (en) 2017-09-28
KR20170113609A (ko) 2017-10-12
AU2016214973A1 (en) 2017-08-24
JP2018504428A (ja) 2018-02-15
CA2975625A1 (en) 2016-08-11
SG11201706285VA (en) 2017-09-28
WO2016123670A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MY197345A (en) Antibody molecules to april and uses thereof
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PH12017500692A1 (en) Antibody molecules to pd-l1 and uses thereof
MX2020006668A (es) Anticuerpos para lilrb2.
JOP20190013A1 (ar) أجسام مضادة لـ (تي آي ام -3)
MX2020001909A (es) Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
MX2020014120A (es) Agonistas parciales del receptor de insulina.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
NZ725568A (en) Modified j-chain
PH12020500225A1 (en) Anti- cd137 antibodies
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017001895A (es) Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc epsilon.
MX2017009960A (es) Union de rutenio e indio unidos a las gastrinas.
MX2016010229A (es) Conjugados del factor vii.
MY195657A (en) Liraglutide In Cardiovascular Conditions
PH12016500044A1 (en) Vasopressin-2 receptor agonists